PIK3CA and neoplasm: Disappointingly, in a phase I trial, combining MEK and PI3K inhibitors have failed to determine the maximally tolerated dose due to a high incidence of adverse effects in patients with KRAS, NRAS, B-Raf or PIK3CA mutations, whereas they have shown synergistic pharmacodynamic tumor activity (NCT01392521) [172].